Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.85 |
| ▸ | HTR3A | P46098 | 4/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | HTR1D | P28221 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.55 |
| ▸ | HTR3B | O95264 | 3/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21548392 | 0.93 | ADRB1 (0.79) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| SCHEMBL6645952 | 0.92 | ADRB1 (1.00) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| SCHEMBL81940 | 0.92 | ADRB1 (1.00) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL3719334 | 0.90 | ADRB1 (0.96) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL314404 | 0.90 | ADRB1 (0.96) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| Water SCHEMBL27430691 | 0.88 | ADRB1 (0.92) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| Dimethylamine SCHEMBL28750709 | 0.86 | ADRB1 (0.88) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| SCHEMBL9881493 | 0.85 | ADRB1 (0.60) | ADRB1HTR3AHTR1AHTR1DHTR1B | |
| SCHEMBL17276864 | 0.83 | ADRB1 (0.68) | ADRB1HTR3AHTR6HTR3EHTR3B | |
| Bicarbonate SCHEMBL11620170 | 0.83 | ADRB1 (0.81) | ADRB1HTR3AHTR6HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199555-A1 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | Université d'Orléans (FR) | 2024-06-20 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020210377-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210383-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| WO-2007053145-A1 | HALOPERIDOL ANALOGS | FLORIDA A & M UNIVERSITY (US) | 2007-05-10 | — | — | WO | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | ADRB1 4772/4885HTR3A 4004/4885HTR1A 4199/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | ADRB1 1409/4885HTR3A 4102/4885HTR1A 2724/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB1 2033/4885HTR3A 2953/4885HTR1A 2339/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB1 3030/4885HTR3A 4724/4885HTR1A 4186/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | ADRB1 917/4885HTR3A 4343/4885HTR1A 3234/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | ADRB1 4624/4885HTR3A 4372/4885HTR1A 4411/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | ADRB1 241/4885HTR3A 3772/4885HTR1A 3061/4885 |
| US-20240199555-A1 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | HTR7, HTR1A, CNR1 | ADRB1 59/4885HTR3A 10/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.